Twist Bioscience (TWST) vs. Its Competitors Head-To-Head Survey

Twist Bioscience (NASDAQ: TWST) is one of 111 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare Twist Bioscience to similar companies based on the strength of its profitability, dividends, earnings, analyst recommendations, valuation, institutional ownership and risk.

Profitability

This table compares Twist Bioscience and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Twist Bioscience N/A N/A N/A
Twist Bioscience Competitors -5,015.13% -60.99% -25.62%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Twist Bioscience and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Twist Bioscience 0 1 2 0 2.67
Twist Bioscience Competitors 736 2493 5715 230 2.59

Twist Bioscience currently has a consensus target price of $25.99, suggesting a potential upside of 2.36%. As a group, “Biological products, except diagnostic” companies have a potential upside of 51.01%. Given Twist Bioscience’s competitors higher probable upside, analysts clearly believe Twist Bioscience has less favorable growth aspects than its competitors.

Institutional and Insider Ownership

48.2% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.1% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Twist Bioscience and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Twist Bioscience $25.43 million -$71.23 million -1.00
Twist Bioscience Competitors $1.00 billion $89.63 million -4.28

Twist Bioscience’s competitors have higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Twist Bioscience Company Profile

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company was founded in 2013 and is headquartered in San Francisco, California.

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply